Table 2.
Clinical pathway for women receiving TGC (n = 284) found to have a functional change in the BRCA1/2 gene or a variant of unknown significance
| BRCA1/2 (n = 26) | VUS (n = 12) | |
|---|---|---|
| n (%) | ||
| State/Territory | ||
| Victoria | 4 (15.4) | 3 (25.0) |
| New South Wales | 2 (7.7) | 1 (8.3) |
| Queensland | 13 (50.0) | 5 (41.6) |
| Western Australia | 6 (23.1) | 2 (16.6) |
| South Australia | 1 (3.8) | – |
| ARIA class | ||
| Metropolitan | 15 (57.7) | 8 (66.6) |
| Regional | 10 (38.5) | 4 (33.3) |
| Missing | 1 (3.8) | – |
| Setting of referral to TGC | ||
| Public | 16 (61.5) | 3 (25.0) |
| Private | 10 (38.5) | 9 (75.0) |
| Onward referral to genetics service | ||
| Victoria | 5 (19.2) | 2 (16.6) |
| New South Wales | 1 (3.8) | – |
| Queensland | 13 (50.0) | – |
| Western Australia | 6 (23.1) | – |
| South Australia | 1 (3.8) | – |